Insulinomas are rare malignant functional pancreatic tumors of the b cells that retain the ability to produce and secrete insulin.
Introduction
Tumors of both the exocrine and endocrine pancreas have been reported in various species, including humans, dogs, cats, and ferrets. [1] [2] [3] [4] [5] [6] Exocrine pancreatic neoplasia mainly includes adenocarcinoma of ductular or acinar origin. 7, 8 Pancreatic endocrine tumors arise from endocrine tissue of the islets of Langerhans, and such tumors may secrete functional hormones that contribute to clinical signs. Pancreatic endocrine tumors are usually malignant in dogs, which is in contrast to humans where they tend to be benign in nature. [1] [2] [3] [4] [5] [6] Specifically, insulinomas (also referred to as b cell insulin secreting tumors or b cell carcinomas) are functional insulinsecreting tumors arising from pancreatic b cells. 3 Insulinomas are the most common endocrine pancreatic tumors described in companion animals. These malignant tumors commonly metastasize to the lymph nodes and liver. 3, 7, 9 Although considered rare, their exact incidence is unknown in dogs. 3 Clinical signs result from insulin-induced neuroglycopenia and increased concentrations of insulin antagonistic counterregulatory hormones. 1, 7, [9] [10] [11] Provisional diagnosis and staging of insulinoma relies on laboratory data, serum insulin concentrations, and imaging exams. A definitive diagnosis typically requires surgical exploration and histopathologic evaluation. 3 The purpose of this article is to review the diagnostic and therapeutic recommendations reported in the veterinary literature and current information on prognosis.
Normal Glucose Homeostasis
The normal pancreas is composed of exocrine cells arranged in acini that secrete digestive enzymes into the duodenum (i.e., trypsin, gallbladder, and duodenum. The PP cells are usually present in low numbers within the islets, and these cells secrete pancreatic polypeptide, a hormone of uncertain function at this time. 7, 9 The b cells account for 60-75% of all islet cells and mainly lie in the middle of each islet. b cells secrete insulin, the dominant glucose-lowering hormone, and amylin. 7, 9 Importantly, glucose influx within b cells is proportional to the blood glucose concentration and is not influenced by the blood insulin level. As a result, intracellular b cell and plasma glucose concentrations are constantly the same, making the b cells keenly sensitive to changes in plasma glucose levels and key regulators of insulin secretion. 1, 2 Physiologic effects of insulin are complex, consisting of rapid, intermediate, and delayed effects on carbohydrate, fat, and protein metabolism. Insulin promotes rapid uptake, storage, and use of glucose by various tissues such as the liver, muscle, and adipose tissue. In the liver, insulin secretion results in decreased glucose production because of reduced gluconeogenesis and increased glycogen synthesis. In muscle, insulin facilitates glucose entry into cells where it is either used as energy or stored in the form of muscle glycogen. In adipose tissue, glucose is a substrate for producing the glycerol portion of fat molecules. 1, 2, 7, 9 Normally, glucose concentration is closely maintained within a narrow physiologic range between 70 mg/dL and 110 mg/dL (3.9-6.1 mmol/L). When the blood glucose concentration rises over a threshold of approximately 100-110 mg/dL, b cells respond by rapidly increasing the rate of insulin secretion. In contrast,
when the blood glucose concentration falls below 60 mg/dL, insulin synthesis and secretion cease, resulting in an increase in the blood glucose concentration. 1 These feedback mechanisms keep the glucose concentration within the relatively narrow physiologic range.
Glucose homeostasis is concurrently impacted by the effects of insulin-antagonistic counterregulatory hormones (e.g., glucagon, catecholamines, adrenocorticotropic hormone, cortisol, growth hormone). 1, 2 In response to decreasing plasma glucose levels, glucagon is secreted from the a cells into the hepatic portal circulation. Glucagon stimulates hepatic glycogenolysis and gluconeogenesis, transiently increasing hepatic glucose production. Epinephrine also has a hyperglycemic effect, both directly (by causing glycogenolysis of the liver) and indirectly (by its lipolytic effect on adipose cells). These direct and indirect effects are mediated through both a-and b-adrenergic receptors. Elevations of growth hormone and cortisol also limit glucose utilization and stimulate glucose production in response to prolonged hypoglycemia over a period of hours to days.
9,11

Clinical Features
Signalment
In previous studies of canine insulinoma, the mean age at time of presentation was between 8.5 yr and 10 yr of age. Historically, the diagnosis of insulinoma depended on demonstrating the features of the Whipple's triad as described in 1935. 25 This consisted of (1) demonstrating subnormal blood glucose levels, (2) recognizing clinical signs of hypoglycemia, and (3) documenting reversibility of signs after resolution of hypoglycemia. 1, 2, 4 This classic route to insulinoma diagnosis is still helpful but has been supplanted by the availability of advanced imaging and the capacity to measure serum insulin levels.
Differential diagnoses for insulinoma include other causes of hypoglycemia that can be broadly classified into four groups. 1, 13, 18 The first group of differentials include diseases associated with excess secretion of insulin or insulin-like factors, including extra pancreatic paraneoplastic syndromes (e.g., hepatoma, leiomyoma, lymphoma) and islet cell hyperplasia. 1, 13, 18 The second group of differentials include diseases with decreased production or increased consumption of glucose, including hypoadrenocorticism, hepatic insufficiency, glycogen storage diseases, and sepsis. 1, 13, 18 The third group of differentials include iatrogenic insulin overdose and toxic causes of insulin release (e.g., sulfonylurea drugs, xylitol, high dose of aspirin, b-blockers). 
Laboratory Data
In cases of canine insulinoma, complete blood cell count, serum biochemistry, and urinalysis are usually unremarkable with the exception of blood glucose levels. 1, 2, 18 Mild hypokalemia has been reported in association with insulinomas. 12, 14, 16 The proposed mechanism of the hypokalemia involves the ability of insulin to stimulate increased potassium uptake into cells. 9 Increased alkaline phosphatase or alanine aminotransferase activities have also been documented. 1, 12, 14, 16 Although this could occur secondary to insulinoma metastasis, these enzyme markers are considered nonspecific as no correlation to an insulinoma has been clearly established by previous authors. 1, 12, 14, 16 The most consistent laboratory finding in dogs with insulinoma is hypoglycemia (,70 mg/dL or 3.9 mmol/L), but glucose levels may vary erratically and require repeated measurements to document an abnormal value. In addition to fluctuating insulin Fructosamine concentration can be used as an indicator of chronic hypoglycemia as this parameter reflects the blood glucose concentrations over the previous 1-2 wk. [30] [31] [32] Initially used to evaluate chronic hyperglycemia in dogs with diabetes mellitus, several studies have reported that dogs with insulinomas do have significantly lower fructosamine concentrations than normal. [30] [31] [32] The turnaround time of this test varies between laboratories, but may take up to several days. Alternatively, random samples can be submitted to establish a blood insulin:glucose ratio, but this technique is not commonly used due to a lack of both sensitivity and specificity. Historically, the amended insulin:glucose ratio (AIGR) can be determined 
Radiographs
Abdominal radiographs are usually unremarkable in dogs with insulinomas due to the small size of most b cell tumors. Lung metastases are rarely found in dogs with insulinomas, and osseous metastases have been reported in only two cases. 13, 16, 17 Although the diagnostic value of plain film radiography is considered limited for insulinoma, such films may reveal abnormal findings in patients with paraneoplastic hypoglycemia due to other tumor types (e.g., leiomyosarcomas). Therefore, thoracic radiography (to detect pulmonary metastasis) should be considered as part of the diagnostic approach to patients with hypoglycemia.
Abdominal Ultrasound
Abdominal ultrasound can be used to visualize mass(es) in the pancreas in many cases ( Figure 1 ). Insulinomas are usually either spherical or lobular and hypoechoic compared with the surroundings tissues. Ultrasound may also be useful to detect metastatic lesions in different organs and lymph nodes. Ultrasonography is known to be operator-dependent, and various factors such as body conformation, abdominal fat, and patient cooperation can interfere with ultrasound interpretation. Depending on the study cited, the sensitivity of abdominal ultrasound in detecting insulinoma varies from 28% to 75%. 5, 6, 16, 17, 23 Endoscopic ultrasonography (EUS) is more sensitive and specific than transabdominal ultrasound in humans, reaching 100% sensitivity and 95% specificity when performed by experienced operators. 39 This technique has been described in dogs, and one report describes diagnosing a 4 mm insulinoma of the left pancreatic limb. 40 Disadvantages of EUS include the steep learning curve, the need for general anesthesia, and the overall lack of EUS availability in most veterinary settings. 40 Contrast-enhanced ultrasonography is now widely use in human medicine for the detection of pancreatic neoplasms. In fact, extrapolated from human oncology, some authors suggest that contrast-enhanced ultrasound exams may better detect mass lesion than helical computed tomography (CT). 41 CT CT should be considered as an additional tool for the diagnosis and preoperative evaluation of insulinomas in dogs. Three studies report using CT for the detection, localization, and staging of insulinomas in dogs. 5, 45, 46 In the first of these studies, CT showed a better sensitivity in the detection of insulinoma masses than either abdominal ultrasound or single-photon emission CT (SPECT) in a case series of insulinomas in 14 dogs. 5 The two latest veterinary studies were performed with dual-phase CT angiography (CTA) on one and three dogs with insulinomas. 45, 46 CTA is based on the delineation of vessels by the radiographic contrast medium. In the case of pancreatic lesions, contrast within the splenic and portal veins may help in locating pancreatic lesions. 47 Due to the highly vascular nature of insulinomas, the mass usually appears highly hyperattenuating during the arterial phase, with small amounts of enhancement seen during the venous phase. 45, 46, 48 Reports using CTA to detect insulinomas are highly promising.
Indeed, in both of the published studies cited herein, CT findings regarding mass and metastasis size/location were similar to surgical findings. 45, 46 In humans, dual phase CT is superior to abdominal ultrasound for detecting and staging insulinomas, and CTA is superior to traditional CT. 48, 49 Nonetheless, further studies are needed to better evaluate the sensitivity of CTA. In-pentetreotide.
Somatostatin Receptor Scintigraphy (SRS) and SPECT
SRS is used in humans to
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The use of SRS in a few dogs has been reported, but it is still unclear if this diagnostic tool could be valuable in a clinical setting. 6, 50, 51 A specific form of SRS called SPECT is under investigation and has a similar sensitivity compared with ultrasound and CT in a series of 14 dogs with insulinomas. 5, 6, 51 However, caution is needed as scintigraphy does not seem to allow appropriate localization of the tumor. 5, 6 For example, Garden et al. (2005) report that the anatomic location of the tumor was established in only one of four dogs diagnosed with insulinoma with scintigraphy. 6 Scintigraphy is a promising imaging technique for the detection of insulinomas and liver and lymph node metastases.
Nonetheless, scintigraphy remains limited by its very restricted availability in veterinary specialty hospitals, its apparent inability to localize lesions, and its relatively expensive cost. 5, 6 One recent study showed that the preoperative localization of insulinomas remains challenging in people regardless of the imaging modality used. When imaging modalities were used alone, the authors reported a diagnostic and localization accuracy of 64% with CT, 75% with MRI, 50% with radiolabeled octreotide (a somatostatin analog) scanning, and 63% with EUS. 52 A combination of modalities (e.g., CTA and MRI or CTA and EUS) 
Cytology and Histopathology
Ultrasound-guided fine-needle aspirate cytology may be used The lack of anaplastic features should not be used to predict the biologic behavior of the tumor, and the likelihood of malignancy must be considered. 54 Thus, the cytologic appearance of insulinomas differs significantly from other neoplasms such as pancreatic adenocarcinoma (i.e., epithelial cell neoplasm) and may be helpful as an adjunctive diagnostic test. 54 Tissue samples are usually fixed in 10% neutral buffered formalin, embedded in paraffin, sectioned, and stained with hematoxylin and eosin ( Figures 3, 4 ). 57 The functionality is then demonstrated by insulin immunohistochemistry ( Figure 5 ). 
Surgical Treatment
Based on the outcome of most dogs with insulinomas after surgical removal, it is suspected that almost 100% of canine cases have metastases at the time of diagnosis. 1 However, at the time of surgery, metastases may be confirmed in only 45-55% of cases, 
Anesthesia and Perioperative Management
Nearly 50% of human insulinoma patients will develop fasting hypoglycemia within 12 hours (with 67 and 95% of patients respectively developing documented hypoglycemia at 24 and 48 hours). 58 Consequently, in contrast to other surgical patients, preoperative fasting is not recommended in patients with insulinoma. Instead, a small meal should be fed 2-3 hr prior to surgery. Anesthetic protocols should take into account the general needs of major abdominal surgery and the specific challenges of the hypoglycemic patient. IV fluids should be given at an adequate rate (generally during the procedure and 1-2 days postoperatively). 18, 59, 61 Pain and stress will lead to a stimulation of the sympathetic nervous system, causing an increase in circulating catecholamines, which will lead to hyperglycemia. Therefore, it is prudent to use locoregional analgesia in combination with opioids to control pain and surgical stress. 62 Commonly, opioids are administered preoperatively with acepromazine or benzodiazepines.
Induction may preferentially be performed with propofol, thiopental, or etomidate, as all of those drugs provide cerebral protection during periods of hypoglycemia. Isoflurane or sevoflurane should be used for maintenance rather than halothane because they are better able to reduce the cerebral metabolic rate.
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a 2 -adrenergic agonists should be avoided because they may suppress the release of insulin, leading to hyperglycemia. 59 
Surgical Exploration and Pancreatectomy
During surgery, the cranial abdominal cavity is explored for evidence of neoplasia. The entire pancreas is examined, both visually and by palpation, evaluating each anatomic area. 61 A partial pancreatectomy is usually performed, as well as resection of grossly visible metastases. Excised tissues are submitted for histopathologic examination. Surgical removal of metastatic lesions should be weighed carefully. Metastectomy not only has the potential to improve the prognosis but also increases the risk of morbidity. 17 The removal of either the peripancreatic or hepatic lymph nodes may increase the risk of interfering with the blood supply of adjacent organs ( Figure 7) . Some authors think that surgical management may be inappropriate when extrapancreatic disease is detected preoperatively. 17 Clinical assessment of metastatic disease should be interpreted cautiously as both imaging modalities and gross observation during surgery may overestimate the presence of metastases.
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Postoperative Complications
Postoperative monitoring of blood glucose and pain should be managed according to published protocols for abdominal surgery and/or pancreatitis. 59 In many cases, euglycemia will be docu- Pancreatitis is a concern following any pancreatic surgery. One study reported pancreatitis in 10% of the dogs postsurgically. 15 Prompt medical treatment and management should be able to minimize morbidity and mortality linked to this complication.
Other complications that have been described following pancreatectomy or metastectomy for insulinomas are ventricular arrhythmias, bleeding, sepsis, leukopenia, cardiac arrest, and syncope. 2, 15, 18, 61 Medical Treatment and Management ( Table 2) Acute Management: Emergent Treatment of Hypoglycemic Crisis
Dextrose Bolus. Hypoglycemic crises (i.e., episodes of clinical signs) should be managed initially with the IV administration of 1 mL/kg of 25% dextrose over 10 min. A normal blood glucose value may be difficult to either achieve or maintain due to ongoing insulin release from the tumor. Thus, the goal of the dextrose bolus is to simply raise blood glucose levels above the threshold that Steroids. Dexamethasone (0.5 mg/kg administered IV over 6 hr q 12-24 hr) is commonly recommended. Other steroids such as prednisone or prednisolone may also be used. These drugs antagonize the effects of insulin, stabilize blood glucose concentrations, and logically are an important part of palliative medical therapy of hypoglycemia caused by hyperinsulinism. 9, 18 See additional information below regarding the use of steroids in the chronic management of insulinomas.
Glucagon. The insulin antagonistic hormone glucagon has a profound hyperglycemic effect by encouraging the breakdown of liver glycogen (glycogenolysis) and by increasing hepatic gluconeogenesis from available amino acids substrates. 7, 9 A constant rate infusion of glucagon has been used in refractory hypoglycemic crisis to maintain euglycemia despite intractable hyperinsulinism.
The initial reported infusion rate is 5 ng/kg/min, which is then adjusted depending on the blood glucose values. Use of glucagon has shown promising results in the management of acute hypoglycemic episodes and, like glucocorticoids, will not stimulate reactive insulin release and rebound hypoglycemia. 65 
Chronic Management
Medical treatment is indicated before surgery and postoperatively, when hyperinsulinemia persists, or in cases in which surgery has not been performed.
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Diet and Exercise. Dogs with insulinomas should be fed at least q 4-8 hr, and food should contain high levels of proteins, fats, and complex carbohydrates. By avoiding simple sugars, an appropriate diet can dramatically reduce the stimulus for tumor insulin release, thereby controlling the clinical signs of hypoglycemia. The only exception is when a patient is actively exhibiting signs of hypoglycemia. In those cases, a rapidly absorbed source of sugar (such as honey, corn syrup, or maple syrup) may be administered The most common side effects reported with the use of diazoxide are anorexia, diarrhea, and vomiting, which may often be prevented by administering diazoxide with meals. Other signs that occur less frequently include hyperglycemia, bone marrow suppression, and sodium retention. 2, 4 Importantly, diazoxide may not be available in many pharmacies and can potentially be prohibitively expensive.
Octreotide. Octreotide, a long-acting synthetic somatostatin analog, has been useful in controlling hormone hypersecretion and clinical signs of insulinomas in humans. 66 It induces hyperglycemia by inhibiting the production of insulin and growth hormone. 7 Canine insulinoma cells have receptors with a high affinity for this drug. 16 That study illustrates the consensus that surgical management is beneficial compared with medical management alone. [13] [14] [15] [16] [17] As reported in several studies, the median survival time in dogs that undergo partial pancreatectomy is 12-14 mo. 16, 18 One study also states that dogs that undergo surgical resection remain normoglycemic for a mean period of 11.6 mo. 13 Benefits of surgery depend on the clinical stage of the disease.
Dogs presenting with metastases at the time of surgery have a dramatically worse prognosis at 1 yr. 13 Caywood et al. (1988) showed that .50% of stage I (i.e., tumor strictly localized to the pancreas) dogs were considered disease-free 14 mo postsurgically compared with ,20% for stage II (i.e., tumor spread to local lymph nodes) and stage III (i.e., tumor with distant metastasis with or without local lymph nodes) dogs. 13 Stage III dogs had a significantly shorter survival time than stage I and II dogs. All stage III dogs died by 18 mo postsurgically. 13 As mentioned previously, postoperative hypoglycemia reportedly has a negative prognostic indicator. 18 However, Tobin et al. (1999) did not report any significant difference in mean survival time between dogs that underwent partial pancreatectomy only (381 days) and dogs that were administered prednisone and diazoxide postsurgically for hypoglycemia (349 days). 16 Dunn et al. (1993) reported identical results. 12 In two other studies, neither signalment of the animal nor clinical signs and their duration, blood insulin concentrations, or tumor location had a significant influence on prognosis. 12, 13 One recent study reports significantly longer survival times compared with older reports. 17 In the recent study, dogs that 
